Patients with secondary AML have poor outcomes

Low survival rates are indicative of an unmet treatment need in patients with secondary AML

Kaplan-Meier curves of survival according to type of AML in intensive therapy patients overall1

aml-overview-1
Adapted from Granfeldt Østgård, et al.
aml-overview-1
Adapted from Granfeldt Østgård, et al.

Relative survival stratified by time and age of AML patients2
 

aml-overview-2
Adapted from National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results Program (SEER) data from 2000-2016.
aml-overview-2
Adapted from National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results Program (SEER) data from 2000-2016.

WHO CLASSIFICATION OF HIGH-RISK AML SUBTYPES

Learn more

sAML: Secondary AML

tAML: Therapy-related AML

References: 1. Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: A national population-based cohort study. J Clin Oncol 2015;33:3641–9. 2. NCI. Surveillance Research Program. SEER Explorer. Accessed August 2023 at: https://seer.cancer.gov/explorer/.

CA-VYX-2400005-E | March 2024